Skip to main content
Figure 1 | Molecular Cancer

Figure 1

From: TRAIL sensitize MDR cells to MDR-related drugs by down-regulation of P-glycoprotein through inhibition of DNA-PKcs/Akt/GSK-3β pathway and activation of caspases

Figure 1

High susceptibility of MDR cells to TRAIL and up-regulation of death receptor and down-regulation of c-FLIP in the cells. (A) mRNA levels of mdr1 in CEM cells and its MDR variants, CEM/VLB10-2, CEM/VLB55-8 and CEM/VLB100 cells were determined by RT-PCR (insert). To determine the growth inhibitory effect of TRAIL, CEM cells and its multidrug-riesistant variants were treated with graded single doses of TRAIL, and the percentage of cell survival was determined after 5 days incubation using the MTT assay. (B) CEM cells and its MDR variants were treated with or without TRAIL (10 ng/ml) for 24 h. Thereafter, the percentage of apoptotic cells in each cell population was determined by Annexin V staining and flow cytometry. Each bar represents the mean ± S.D. of triplicate experiments. *p < 0.05, **p < 0.01, ***p < 0.005 versus TRAIL untreated control cells. (C) mRNA levels of DR4/DR5 and c-FLIPL/S in CEM cells and its MDR variants were determined by RT-PCR analysis. β-Actin (Actin) was used as a loading control.

Back to article page

Molecular Cancer

ISSN: 1476-4598